Table 2.

Clinical and pathological features of the 142 gastric cancer patients and correlation with HER2 status.

HER2-Positive (n = 19)			HER2-Negative (n = 123)
Features	Cases	Percentage%	Cases	Percentage%	p
Age					0.085
Mean	61		66
≤70	14	16.86%	70	84.33%
≥71	5	8.47%	53	91.53%
Sex					0.578
Male	13	14.60%	76	85.40%
Female	6	11.30%	47	88.70%
Location					0.041
Cardia	1	4.30%	22	95.70%
Fundus	1	100%	0	0.0%
Corpus	8	13.80%	50	86.20%
Antrum	9	15.30%	50	84.70%
Histological type					0.013
Intestinal	16	21.10%	60	78.90%
Diffuse	2	3.50%	55	96.50%
Mixed	1	11.10%	9	88.90%
Pathological diagnosis					0.267
Adenocarcinoma	18	17.30%	86	82.70%
Signet ring cell carcinoma	1	2.90%	33	97.10%
Small cell carcinoma	0	0.00%	2	100%
Undifferentiated carcinoma	0	0.00%	1	100%
Squamous cell carcinoma	0	0.00%	1	100%
Degree of differentiation					0.178
G1	0	0.00%	18	100%
G2	8	17.40%	38	82.60%
G3	11	14.90%	63	85.10%
T					0.25
Tis	0	0.00%	6	100%
T1a/T1b	0	0.00%	15	100%
T2	1	4.80%	20	95.20%
T3	11	19.30%	46	80.70%
T4a/T4b	7	16.27%	36	83.73%
N					0.455
N0	5	9.30%	49	90.70%
N1	5	13.20%	33	86.80%
N2	3	13.00%	20	87.00%
N3a/N3b	6	22.20%	21	77.80%
M					0.005
M0	14	10.90%	115	89.10%
M1	5	38.50%	8	61.50%
Stage					0.012
IA/IB	1	3.10%	32	96.90%
IIA/IIB	6	12.80%	41	87.20%
IIIA/IIIB/IIIC	6	13.00%	40	87.00%
IV	6	37.50%	10	62.50%
Lymphatic involvement				0.227
Yes	11	17.20%	53	82.80%
No	8	10.30%	70	89.70%
Vascular involvement				0.292
Yes	10	16.90%	49	83.10%
No	9	10.80%	74	89.20%
Perineural involvement				0.763
Yes	7	14.60%	41	85.40%
No	12	12.80%	82	87.20%
Adjuvant chemotherapy				0.005
Yes	11	25.60%	32	74.40%
No	8	8.10%	91	91.90%
Survival				0.209
Living	5	8.90%	51	91.10%
Deceased	14	16.30%	72	83.70%

HER2: Human Epidermal Growth Receptor 2.